Psilocybin-assisted therapy is a structured treatment that combines the psychoactive compound found in certain mushrooms with professional psychological support. Unlike traditional antidepressants taken daily, this approach typically involves one to three supervised dosing sessions over several weeks, each lasting six to eight hours, bookended by preparation and follow-up therapy. The goal is to produce lasting changes in mood, thought patterns, and outlook through a combination of the drug’s effects on the brain and guided therapeutic work.
How a Treatment Course Works
The therapy unfolds in three distinct phases: preparation, dosing, and integration. During preparation, you meet with your therapists (most protocols use two) to build trust, set intentions for the experience, and learn what to expect from the drug’s effects. This phase can span one or several sessions depending on the protocol.
The dosing session itself takes place in a comfortable, carefully designed room rather than a clinical-looking setting. You take psilocybin in capsule form, then spend the next six to eight hours lying down, often wearing an eye mask and listening to music, while therapists remain present to provide support. The experience can include vivid imagery, intense emotions, a sense of dissolving boundaries between self and surroundings, and what researchers call “mystical-type” experiences. It can also be challenging, with periods of anxiety or difficult emotions surfacing.
In the days and weeks that follow, you return for integration sessions. These are where the therapeutic heavy lifting often happens. You process what came up during the dosing session, examine new perspectives on long-standing problems, and work with your therapist to translate any insights into concrete behavioral changes. The entire treatment course, from first preparation session through final integration, typically spans several weeks to a few months.
What Psilocybin Does in the Brain
Psilocybin is converted in the body to psilocin, which activates a specific type of serotonin receptor. This triggers a cascade of effects that go well beyond the hours of the acute experience. The drug reverses stress-related damage to brain cells by boosting signaling between neurons, increasing the release of a key growth factor that supports neuron health, and ultimately promoting the growth of new neural connections. Brain imaging studies show increased dendritic branching (the tree-like extensions neurons use to communicate), greater density and size of synaptic spines, and improved connectivity across brain circuits.
In practical terms, this means psilocybin appears to open a window of heightened brain plasticity. Neural pathways that may have become rigid, particularly in conditions like depression where repetitive negative thought loops dominate, become more flexible. This is likely why the therapeutic effects can persist for months after just one or two doses. The drug doesn’t just alter mood temporarily; it changes the physical structure and connectivity of brain cells in ways that outlast its presence in the body.
What the Clinical Evidence Shows
The strongest evidence so far is for depression. A systematic review and meta-analysis of clinical trials found pooled remission rates of 45% for psilocybin compared to 22% for comparators. Response rates similarly favored psilocybin by a significant margin. These results are particularly notable because many participants had treatment-resistant depression, meaning they had already tried and failed to improve with conventional antidepressants.
The therapy has also shown striking results for people facing terminal illness. A 2016 study of 29 adults with life-threatening cancer found that psilocybin-assisted therapy improved depression, anxiety, spiritual well-being, quality of life, and feelings of hopelessness at seven weeks. Those effects held at 6.5 months and were still detectable 4.5 years later. For people grappling with existential distress at the end of life, this durability from a single treatment course is remarkable compared to the daily dosing most psychiatric medications require.
Side Effects and Safety Profile
The most common side effects during and shortly after sessions include elevated blood pressure, headaches, nausea, vomiting, fatigue, and anxiety. These are generally transient and resolve within hours to days. No deaths have been attributed to psilocybin in clinical trials, and systematic reviews of the available safety data generally support the therapy’s safety profile within controlled settings.
Suicidal ideation and behavior were observed infrequently in trials and occurred mainly in participants who already had a history of suicidal thoughts or attempts. This is one reason screening is so rigorous before treatment.
Who Can and Cannot Receive Treatment
Clinical trials apply strict screening criteria, and the same principles will likely carry into any approved medical use. People with a personal or family history of psychotic disorders (schizophrenia, schizoaffective disorder, bipolar disorder with psychotic features) are excluded because psilocybin can trigger or worsen psychosis in vulnerable individuals. Active substance use disorders, significant cardiovascular problems such as uncontrolled high blood pressure, seizure disorders, and pregnancy are also disqualifying.
Certain medications create dangerous interactions. Monoamine oxidase inhibitors, some antipsychotics, and tramadol must be stopped well before treatment. Even common substances like alcohol and nicotine are restricted in the 72 hours before a session. People with borderline personality disorder, active suicidal plans, or current PTSD or OCD diagnoses have also been excluded from major trials, though this may reflect caution rather than established harm, and separate research is exploring some of these populations.
Legal Status and Access
Psilocybin remains a Schedule I controlled substance under U.S. federal law, meaning it has no approved medical use in most of the country. However, the regulatory landscape is shifting quickly. The FDA has granted Breakthrough Therapy designation to psilocybin programs for treatment-resistant depression and major depressive disorder, and in 2025, the agency issued national priority vouchers to companies studying these applications, signaling an accelerated path toward potential approval.
Two states have moved ahead independently. Oregon began licensing psilocybin service centers in 2023 under a framework created by Ballot Measure 109, passed by voters in 2020. The Oregon Health Authority licenses and regulates every step from manufacturing to administration. You do not need a diagnosis or prescription to access services, but you must work with a licensed facilitator at an approved service center. Colorado has established a similar but distinct system with two tiers of facilitator licensure. The standard Facilitator license requires 150 hours of approved training, a 40-hour practicum, 50 hours of consultation, and 20 hours of continuing education annually. A Clinical Facilitator must meet all those requirements and also hold an active clinical license.
Doses used in clinical research are carefully controlled. Most trials have administered psilocybin on a weight-adjusted basis, typically in the range of 20 to 30 milligrams per 70 kilograms of body weight. A fixed dose of approximately 25 milligrams is currently being evaluated in registration trials for major depressive disorder, which could simplify dosing if the therapy gains FDA approval. These are synthetic, pharmaceutical-grade capsules, not raw mushrooms, ensuring precise and consistent dosing.
How It Differs From Taking Psilocybin on Your Own
The “assisted therapy” distinction is not just a formality. The clinical outcomes seen in trials depend on the full package: careful screening, therapeutic preparation, professional support during a potentially intense and disorienting experience, and structured integration afterward. The preparation phase builds a relationship with the therapist that makes it safer to confront difficult emotions during the session. The integration phase is where fleeting insights become lasting changes in how you relate to yourself and your problems.
Taking psilocybin outside a therapeutic context carries risks that the clinical framework is specifically designed to minimize: psychological distress without support, dangerous behavior in an uncontrolled environment, and the absence of follow-up work to make sense of the experience. The drug opens a door, but the therapy is what helps people walk through it in a meaningful direction.